About This Trial

Master protocol evaluating pembrolizumab combinations across 12 tumor types in adjuvant setting.

Primary Endpoints

  • Disease-free survival
  • Overall survival

Latest Update

February 2026

Positive results in renal cell carcinoma arm. Two additional tumor types showing promising interim data.